Clinical trial
A Trial for Patients With Advanced/Recurrent Endometrial Cancer
NCT00377520 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00377520 |
|---|---|
| Title | A Trial for Patients With Advanced/Recurrent Endometrial Cancer |
| Official title | A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma |
| Lead sponsor | Eli Lilly and Company, Industry |
| Collaborators | Gynecologic Oncology Group |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Neoplasms, Neoplasms by Site, Urogenital Neoplasms, Genital Neoplasms, Female, Uterine Neoplasms, Endometrial Neoplasms, Cancer of Endometrium, Endometrial Cancer, Cancer of the Endometrium and 2 more |
| Intervention type | Drug |
| Interventions | pemetrexed |
| Enrollment | 27 |
| Start date | Sep 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Sep 1, 2008 |
| First posted | Sep 18, 2006 |
| Last update posted | Nov 20, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: